Organ-on-a-Chip

Organ-on-a-Chip is a microfabricated microfluidic cell-culture system—classified in regulatory bioengineering as a microphysiological system (MPS)—lined with living human parenchymal, epithelial, and vascular endothelial cells that reconstitutes the minimal functional unit of a human organ under dynamic fluid perfusion, trans-tissue biochemical gradients, and cyclic mechanical deformation. Pioneered in its dual-channel barrier architecture in 2010 by Dan Huh, Donald E. Ingber, and colleagues at the Wyss Institute with the breathing human lung-on-a-chip, organ-on-a-chip platforms bridge the gap between static plastic dishes—which lack fluid shear stress and vascular interfaces—and animal models whose species-specific transporters and immune receptors often mispredict human drug responses.

Whereas self-organizing three-dimensional spheroids rely on intrinsic morphogenesis inside static gels, organ-on-a-chip devices impose engineered channel geometry, metered vascular-to-parenchymal drug dosing, and continuous electrical and optical readout, increasingly merging with stem-cell constructs in organoid-on-a-chip hybrids.

Soft Lithography in PDMS Versus Non-Sorptive Thermoplastics

First-generation chips are fabricated via soft lithography (introduced by George M. Whitesides) in polydimethylsiloxane (PDMS), an optically clear, gas-permeable silicone elastomer cast against photolithographically patterned SU-8 master molds with microchannel widths of 50 to 1,000 μm. Stacked apical parenchymal and basal vascular microchannels are separated by a flexible microporous (0.4–8.0 μm pores) membrane coated with extracellular matrix proteins (collagen IV, fibronectin, laminin), flanked by pneumatic vacuum chambers that apply cyclic physiological stretch (such as 10% strain at 0.2 Hz in alveolar lung chips or 0.15 Hz peristalsis in gut chips).

Because hydrophobic PDMS absorbs lipophilic small molecules (octanol–water partition coefficient log P > 2.5, such as diazepam or steroid hormones) out of perfused media, quantitative pharmacokinetic screening chips increasingly employ injection-molded non-sorptive thermoplastics—notably cyclic olefin copolymer (COC), cyclic olefin polymer (COP), and polycarbonate—that preserve exact unbound drug concentrations.

Low-Reynolds-Number Flow and Wall Shear Stress

At sub-millimeter hydraulic diameters (D_h ≈ 10⁻⁴ to 10⁻³ m) and physiological flow speeds (u ≈ 0.1–10 mm/s), microfluidic perfusion operates inside the viscous-dominated laminar regime where the dimensionless Reynolds number (Re) sits below unity:

Re = (ρ · u · D_h) / μ < 1

Without turbulent eddies, parallel laminar streams mix transversely by molecular diffusion alone (governed by the Péclet number, Pe = u · L / D_mol), sustaining stable morphogen or oxygen gradients. Across a rectangular vascular channel of width w and height h (w ≫ h) at volumetric flow rate Q and dynamic viscosity μ, Poiseuille flow imposes a uniform wall shear stress (τ) onto the endothelial lumen:

τ = (6 · μ · Q) / (w · h²)

Delivering physiological capillary-to-arteriolar shear stresses of 1 to 15 dyn/cm² (0.1–1.5 Pa) activates endothelial PECAM-1 / VE-cadherin / VEGFR2 and PIEZO1 mechanosensors, inducing KLF2/KLF4 transcription, glycocalyx maturation, nitric oxide synthesis, and tight-junction sealing absent in static Transwell cultures.

Hypoxia-Enhanced Neurovascular Unit Chips

Static Transwell models of the human blood-brain barrier exhibit low electrical resistance (<200 Ω·cm²) and downregulated efflux transporters. Tae-Eun Park, Donald E. Ingber, and colleagues (2019) differentiated human induced pluripotent stem cell lines into brain microvascular endothelial cells under embryonic-mimetic 5% O₂ hypoxia (activating HIF1A-driven CLDN5, GLUT1, and ABCB1) before co-culturing them under laminar shear opposite human brain pericytes and astrocytes. Monitored by integrated four-point impedance electrodes, hypoxia-enhanced human BBB chips sustain in-vivo-level transendothelial electrical resistance (TEER ≈ 1,500 to >3,000 Ω·cm²) for over two weeks, block paracellular dextran leakage, efflux P-glycoprotein substrates, and predict human transferrin receptor (TfR1) antibody shuttling across species barriers.

In a fluidically coupled three-chip neurovascular unit (influx BBB chip → neuronal chip → efflux BBB chip), Ben M. Maoz, Kit Parker, Donald E. Ingber, and colleagues (2018) used isotope-tracing metabolomics to prove that endothelial and astrocytic pyruvate/glutamine metabolism directly supplies glutamate and GABA neurotransmitter synthesis inside human cortical neurons.

Microelectrode/Optical Brain Chips and Gut–Liver–Brain Circuits

Advanced brain-on-a-chip devices seat whole or sliced human cortical, hippocampal, or midbrain organoids directly atop transparent indium-tin-oxide or CMOS planar microelectrode arrays, optical porphyrin dissolved-O₂ luminescence optodes, and amperometric glutamate, lactate, and dopamine microbiosensors. Continuous laminar microperfusion replenishes oxygen and clears acidic catabolites over multi-month cultures while tracking local field potentials, single-unit spike trains, and network burst synchrony during pharmacological challenge or closed-loop electrical stimulation.

At the systemic level, automated liquid-handling interrogator instruments and pumpless gravity-rocked multi-organ ("body-on-a-chip") circuits fluidically couple anaerobic microbiome-colonized gut-on-a-chip barriers (maintaining <0.5% luminal O₂ across mucus-secreting villi), cytochrome-P450-competent liver-on-a-chip sinusoids, proximal-tubule kidney-on-a-chip clearance channels, and BBB/brain-on-a-chip modules scaled by physiological blood residence times and organ volume ratios. Integrated with quantitative physiologically based pharmacokinetic (PBPK) differential-equation models—and formally authorized as non-animal preclinical efficacy and toxicology evidence under the U.S. FDA Modernization Act 2.0 (2022)—linked multi-organ chips predict human oral bioavailability, first-pass hepatic bioactivation of prodrugs into neuroactive or neurotoxic species, blood–brain permeability coefficients, and gut-microbiome short-chain fatty acid modulation of central neuroinflammation.

How does an organ-on-a-chip differ from a three-dimensional organoid?

A 3D organoid develops via bottom-up stem-cell self-organization in static gel drops, capturing complex embryonic cytoarchitecture but lacking controlled vascular shear or luminal access. An organ-on-a-chip uses top-down microfluidic channels and flexible membranes to apply metered wall shear stress (1–15 dyn/cm²), cyclic strain, and inline TEER/sensor readout; organoid-on-a-chip platforms combine both by perfusing stem-cell organoids inside engineered microchannels.

Why are non-sorptive thermoplastics such as COC replacing PDMS in pharmaceutical chips?

Polydimethylsiloxane (PDMS) has a porous hydrophobic polymer network that sequesters lipophilic drugs (log P > 2.5) into the chip walls, depleting free drug levels in the perfusate and distorting potency or toxicity curves. Dense thermoplastics such as cyclic olefin copolymer (COC) and polycarbonate resist small-molecule absorption and support scalable injection molding.

Why must a blood–brain barrier chip achieve TEER above 1,000 Ω·cm²?

Transendothelial electrical resistance (TEER) quantifies resistance to ionic current across an endothelial monolayer normalized by area. Low TEER (<200 Ω·cm²) reflects paracellular gaps through which polar drugs leak passively; reaching TEER > 1,000–2,000 Ω·cm² verifies continuous claudin-5/occludin tight junctions that restrict transport to authentic carrier, ABC efflux, or receptor-mediated transcytosis pathways.

1. Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. https://doi.org/10.1126/science.1188302
2. Bhatia, S. N., & Ingber, D. E. (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. https://doi.org/10.1038/nbt.2989
3. Maoz, B. M., Herland, A., FitzGerald, E. A., Grevesse, T., Vidoudez, C., Pacheco, A. R., ... & Parker, K. K. (2018). A linked organ-on-chip model of the human neurovascular unit reveals the metabolic coupling of endothelial and neuronal cells. Nature Biotechnology, 36(9), 865–874. https://doi.org/10.1038/nbt.4226
4. Park, T. E., Mustafaoglu, N., Herland, A., Hasselkus, R., Mannix, R., FitzGerald, E. A., ... & Ingber, D. E. (2019). Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies. Nature Communications, 10(1), 2621. https://doi.org/10.1038/s41467-019-10588-0
5. Ingber, D. E. (2022). Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics, 23(8), 467–491. https://doi.org/10.1038/s41576-022-00466-9